Abiopharma

🔍 Shuda Scott (Director)

Company: InfuSystem Holdings, Inc (INFU)

Report Date: 2025-07-07

Detailed Transactions and Holdings:

• Sold 2,242 shares of Common Stock (Direct)
  Date: 2025-07-07 | Code: J | equity_swap_involved: 0 | shares_owned_after: 99,752.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 5,752 shares of Common Stock at $9.67 per share (Direct)
  Date: 2025-08-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 94,000.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-07-07 | Code: H | nature_of_ownership: Footnote 1 | shares_owned_after: 298,383.00 | Footnotes: F1

Footnotes:

• F1: Mr. Shuda serves as Managing Director of (i) TSV Investment Partners, LLC, which is the sole general partner of Meridian OHC Partners, LP ("Meridian") and (ii) BlueLine Partners, LLC, which is the sole general partner of BlueLine Capital Partners II ("BlueLine"). Accordingly, Mr. Shuda holds voting and dispositive power over the Common Stock held by Meridian and BlueLine. Mr. Shuda disclaims beneficial ownership for purposes of Rule 13d-3 with respect to the Common Stock held by Meridian and BlueLine.
• F2: The transactions relate to shares originally held by a partnership, Meridian TSV II, LP, that was dissolved with the result of Mr. Shuda taking custody of the shares. In July 2025, Mr. Shuda distributed shares to one former member of the partnership and in August 2025, Mr. Shuda sold shares for the benefit of the other partners. No shares remain relating to the partnership and no other shares are planned to be sold. The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.83. The reporting person undertakes to provide the company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.